Long-term treatment with rotigotine in drug-naïve PSP patients

Tommaso Schirinzi, Valerio Pisani, Paola Imbriani, Giulia Di Lazzaro, Simona Scalise, Antonio Pisani

Research output: Contribution to journalArticlepeer-review


Progressive supranuclear palsy (PSP) is a severe neurodegenerative disease still lacking of alleviating treatments for either cognitive or motor disturbances. Aimed at widening the spectrum of therapeutic options, here, we describe efficacy and safety of a long-term treatment with Rotigotine, a non-ergolinic dopamine agonist, in PSP. Seven PSP drug-naïve patients, presenting with Richardson’s syndrome, received up to 6 mg/24 h transdermal patch for 42 weeks as unique therapy. Adverse effects were recorded; efficacy was measured by comparing baseline and final treatment scores of Montreal Cognitive Assessment (MoCA), Unified Parkinson Disease Rating Scale part3, and PSP rating scale (PSP-RS). At the end of our observation, no significant adverse events occurred; the cognitive item of PSP-RS was improved and MoCA score was similar at baseline. Contrariwise, motor disturbances worsened according to disease progression. Our observation thus suggests that long-term treatment with low doses of rotigotine is well tolerated and may support cognitive functions of PSP patients.

Original languageEnglish
JournalActa Neurologica Belgica
Publication statusAccepted/In press - Jan 1 2018


  • Dementia
  • Parkinsonism
  • Progressive supranuclear palsy
  • PSP
  • Rotigotine

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Long-term treatment with rotigotine in drug-naïve PSP patients'. Together they form a unique fingerprint.

Cite this